Coherus Oncology, Inc.CHRSNASDAQ
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
14.45%
↓ 87% below average
Average (39q)
112.59%
Historical baseline
Range
High:3976.41%
Low:-159.19%
CAGR
-2.1%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 14.45% |
| Q2 2025 | 38.68% |
| Q1 2025 | -75.62% |
| Q4 2024 | -59.45% |
| Q3 2024 | 41.24% |
| Q2 2024 | 3976.41% |
| Q1 2024 | -87.51% |
| Q4 2023 | -83.38% |
| Q3 2023 | 23.61% |
| Q2 2023 | 117.63% |
| Q1 2023 | -50.04% |
| Q4 2022 | 205.69% |
| Q3 2022 | -79.15% |
| Q2 2022 | -3.69% |
| Q1 2022 | -17.17% |
| Q4 2021 | 0.07% |
| Q3 2021 | -13.71% |
| Q2 2021 | -6.06% |
| Q1 2021 | -23.52% |
| Q4 2020 | -5.55% |
| Q3 2020 | -16.72% |
| Q2 2020 | 14.83% |
| Q1 2020 | -5.80% |
| Q4 2019 | 10.28% |
| Q3 2019 | 27.05% |
| Q2 2019 | 137.52% |
| Q1 2019 | 230.79% |
| Q4 2018 | 3.89% |
| Q3 2018 | -4.61% |
| Q2 2018 | -4.18% |
| Q1 2018 | 17.70% |
| Q4 2017 | 27.44% |
| Q3 2017 | -34.02% |
| Q2 2017 | 40.68% |
| Q1 2017 | 7.83% |
| Q4 2016 | -159.19% |
| Q3 2016 | 290.89% |
| Q2 2016 | 2.79% |
| Q1 2016 | -29.62% |
| Q4 2015 | 33.08% |